BTK and B-cell chronic lymphocytic leukemia: In 2014, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, at a dose of 420 mg po daily, was approved as second line treatment for chronic lymphocytic leukemia (CLL), based on the RESONATE landmark trial, leading to FDA approval for this indication.